Earnings call transcript: Core & Main Q4 2025 beats EPS estimates, stock dips

Core & Main beat EPS with adjusted EPS of $0.52 versus $0.33 consensus (+57.6%) while revenue slightly missed at $1.58B vs $1.59B (-0.63%). Gross margin expanded to 27.1% (+50 bps) and adjusted EBITDA was $167M (10.6% margin); full-year net sales were $7.65B, adjusted EBITDA $931M and adjusted EPS $2.97. Management guided FY2026 net sales ~$7.8-7.9B and adjusted EBITDA $950-980M, reiterated M&A and greenfield expansion plans, and continued buybacks ($155M repurchased in FY2025, $39M subsequent), but warned of residential weakness, PVC/resin and fuel-driven cost risks and broader geopolitical uncertainty. Shares fell ~1.28% pre-market to $47.79, reflecting mixed investor reaction to the strong EPS but cautious outlook.

Analysis

Core & Main’s playbook—private-label mix shift, targeted national teams for complex projects, and disciplined inventory timing—creates convexity: modest execution wins can lift gross margin more than linear top-line growth would imply. As a rule of thumb in specialty distribution, each 1ppt increase in proprietary-sourced mix typically translates to ~15–25bps of gross margin expansion; if management can double private-label penetration over 12–24 months that’s a non-trivial earnings lever independent of broader end-market recovery.

The company’s ticket into large, multi-year meter and treatment-plant contracts is a double-edged sword: they raise average contract size and stickiness (raising lifetime value per customer) but also amplify working-capital swings and project execution risk. Expect weeks-to-months volatility in receivables/inventory around big rollouts; a single delayed municipal procurement cycle or supplier lead-time shock could compress near-term cash conversion while leaving long-term share gains intact.

PVC/resin price dynamics are the primary macro swing factor to watch. A run-up in resin over the next 1–3 quarters would restore pricing tails and tighten spreads for distributors who fronted inventory; conversely, prolonged weakness in residential demand or a broader construction slowdown could expose SG&A leverage limits despite margin initiatives. Key near-term catalysts: contract awards cadence (30–90 days), resin price inflection (weeks–quarters), and M&A/greenfield execution (quarters).

Key Decisions for Investors

• Long CNM equity (6–12 month horizon): buy on pullbacks into operational drawdowns tied to weather or quarter-seasonality. Rationale: asymmetric upside from margin expansion + large-project backlog; risk: execution or municipal funding shock. Target/risk profile: aim for ~30% upside vs ~20–25% downside (use position sizing to limit fund-level drawdown).
• Buy CNM 9–12 month call spread to cap premium (debit), delta-positive but limited risk: use a near-the-money long call and sell a higher strike ~20–30% out to finance. Rationale: captures margin recovery and contract wins while limiting time decay if residential weakness persists.
• Pair trade for risk-managed exposure: long CNM stock + buy 3–6 month puts on CNM (protective put). Rationale: keep upside exposure to private-label and large-project execution while hedging near-term macro/contract execution risks. Hedge size: 20–40% of equity exposure depending on risk tolerance.
• Event-driven small allocation: go long CNM around confirmed resin price upticks or announced large municipal contract awards (monitor press releases/SEC filings). Rationale: these are high-probability catalysts that convert latent gross-margin tailwinds into realized EBITDA upside within 1–3 quarters.